Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00077298 · ClinicalTrials.gov registry record · Phase 2

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

A Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
70
Enrollment target
1
Study location

NCT00077298 is a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants, above the 24-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (192% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00077298, a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

This randomized phase II trial is studying giving bevacizumab and cetuximab together with irinotecan to see how well it works compared to giving bevacizumab and cetuximab alone in treating patients with irinotecan-refractory metastatic colorectal cancer. Monoclonal antibodies such as cetuximab and bevacizumab can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or deliver tumor -killing substances to them. Drugs used in chemotherapy, such as irinotecan, also work in different ways to kill tumor cells or stop them from growing. Giving cetuximab and bevacizumab together with irinotecan may improve the ability to block tumor growth.

Conditions Studied

Recurrent Colon Cancer Recurrent Rectal Cancer Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • BIOLOGICAL cetuximab
  • BIOLOGICAL bevacizumab
  • DRUG irinotecan hydrochloride

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2003-12
Est. Completion 2007-07
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00077298

The ClinicalTrials.gov registry entry for NCT00077298 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (192% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Recurrent Colon Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00077298 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00077298 about?

NCT00077298 is a clinical study titled "Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer". This randomized phase II trial is studying giving bevacizumab and cetuximab together with irinotecan to see how well it works compared to giving bevacizumab and cetuximab alone in treating patients with irinotecan-refractory metastatic colorectal cancer. Monoclonal antibodies such as cetuximab and b...

What is the current status of trial NCT00077298?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2003-12. Estimated completion is 2007-07.

What conditions does trial NCT00077298 study?

This clinical trial studies the following conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer.

What interventions are being tested in trial NCT00077298?

The interventions under investigation include: laboratory biomarker analysis (OTHER), cetuximab (BIOLOGICAL), bevacizumab (BIOLOGICAL), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00077298?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00077298 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Colon Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Colon Cancer

All registered trials for this condition

Recurrent Rectal Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.